Who Is Your Audience? 你的听众是谁？ - Foley & Lardner
Who Is Your Audience? 你的听众是谁？ - Foley & Lardner
Who Is Your Audience? 你的听众是谁？ - Foley & Lardner
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Getting the Most Value From <strong>Your</strong><br />
Company’s Intellectual Property in<br />
Technology-Driven Global Markets<br />
技术主导的全球市场中以公司的知识产<br />
权实现价值最大化<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP • Attorney Advertising • Prior results do not guarantee a<br />
similar outcome • 321 N. Clark Street, Suite 2800, Chicago, IL 60654 • 312.832.4500<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
Stephen Bent (柏思迪)<br />
FOLEY & LARDNER LLP<br />
Washington, D.C.<br />
柏思迪<br />
美国富理达律师事务所 华盛顿特区办公室<br />
<strong>Who</strong> <strong>Is</strong> <strong>Your</strong> <strong>Audience</strong>?<br />
你的听众是谁?<br />
Companies looking for market expansion and new technology<br />
opportunities<br />
Pooled investment vehicles that provide young, dynamic firms with<br />
growth capital<br />
– Angel networks<br />
– Venture capital funds<br />
– Certain hedge funds<br />
寻求开拓新市场与新技术机遇的公司<br />
投资机构为新兴的,有活力的公司提供全球资本<br />
– 天使投资网络<br />
– 风险投资基金<br />
– 对冲基金<br />
1<br />
2<br />
1
What Do They Want? (1)<br />
什么是投资人所想要的?(1)<br />
Focused, Informed Management Team<br />
Innovative Science<br />
– More than a “me too” technology<br />
– Satisfies unmet need<br />
– Potential for IP asset development<br />
Unified, Comprehensive Business Plan<br />
For Funds, A Well-Defined Exit Strategy<br />
For Partners, The Prospect of Continuity<br />
专注,信息灵通的管理团队<br />
创新科技<br />
– 比“模仿”技术更好的技术<br />
– 满足人们尚未“满足”的需求<br />
– 知识产权资产的发展前景<br />
标准化,综合性的商业计划<br />
对于风险投资基金来说,有很好的退出机制<br />
对于合作伙伴来说,有光明的发展前景<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
What Do They Want? (2)<br />
什么是投资人所想要的?(2)<br />
Strategic collaboration and acquisition have<br />
displaced IPO as the most common liquidity<br />
events worldwide<br />
Underscoring company value through IP-related<br />
planning and effective operation/structure will<br />
attract investors and business partners alike<br />
战略性的合作与收购已经取代公司上市成为世界范围<br />
内最普遍的投资清偿<br />
通过关于知识产权计划、实施和结构,突出公司的价<br />
值,将能吸引投资者和商业合作伙伴<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
3<br />
4<br />
2
Indicia of “Good Governance”<br />
“良好管理”的指标<br />
Audited financial statements<br />
and internal controls<br />
Independent directors<br />
Few related-party transactions<br />
Minimal litigation and other contingencies<br />
Well-defined criteria for gauging progress<br />
经审计的财务报告和内部控制<br />
独立董事<br />
很少关联方交易<br />
较少的诉讼以及其它意外<br />
对于公司的成长测定有明确的界定标准<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
Integrate R&D Goals With Business Plan<br />
研发目标与公司的商业计划相配套<br />
Identify commercialization target(s) and time frame<br />
Link market projections with IP potential<br />
– Crowded technology field (“prior art”)?<br />
– Proper timing/content of patent filings?<br />
– Freedom to operate?<br />
明确商业化目标以及时间期限<br />
将市场预测与知识产权培养相结合<br />
– 是否是现有技术扎堆的领域 (“现有技术”)?<br />
– 申请专利的内容以及时机是否合适?<br />
– 是否可自由实施?<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
5<br />
6<br />
3
Realizing Value from IP Assets (1)<br />
知识产权资产价值的实现(1)<br />
Exclusive field-of-use licensing<br />
Non-exclusive license combined with know-how transfer/technical<br />
support<br />
Sale for cash and/or stock, possibly<br />
with performance-based “tail”<br />
Transfer via corporate transaction, e.g., forming joint venture that<br />
receives IP contributions from JV partners<br />
Securitization – Loan backed by IP assets<br />
专属领域的使用许可<br />
普通许可与技术诀窍转移或技术支持相结合<br />
以知识产权潜在价值为基准,以现金或股票形式出售知识产权<br />
通过公司交易转移知识产权,例如,一方以知识产权出资而组建的合资公司<br />
融资-以知识产权资产为抵押融资<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
Realizing Value from IP Assets (2)<br />
知识产权资产价值的实现(2)<br />
Parent Company<br />
母公司<br />
Related<br />
Related Operating Operating Units<br />
关联操作公司 Units<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
Licenses<br />
许可<br />
Royalties<br />
许可费<br />
IP Rights<br />
知识产权<br />
Stock<br />
股票<br />
Investment<br />
Investment Holding Company Holding<br />
投资控股公司<br />
Company<br />
Licenses<br />
许可<br />
Royalties<br />
许可费<br />
Unrelated Parties<br />
Unrelated 非关联方 Parties<br />
7<br />
8<br />
4
Examples from Life-Science Sectors<br />
有关生命科学产业的例子<br />
JV between Positron Corp. (Houston) and Neusoft Medical Systems<br />
(Shenyang) enriched by Neusoft IP<br />
HUYA Bioscience (San Diego) co-develops drug candidate with<br />
Chinese IPR source, which holds IP rights in PRC<br />
NeoStem (New York) acquires China Biopharmaceuticals Holdings,<br />
partly for access to propriety product pipeline of sub, Suzhou Erye<br />
Pharmaceutical Co.<br />
沈阳东软医疗系统有限公司 与Positron 公司(位于休斯敦)组建的合资公<br />
司,获得东软的知识产权支持<br />
HUYA 生物科技公司(位于圣地牙哥)与拥有自主知识产权的中方联合开发<br />
新药,并且在中国境内对该新药拥有知识产权<br />
NeoStem(位于纽约)收购中国制药公司,部分是为了获得苏州二叶制药公<br />
司专有的产品的产品线<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
What’s Really Important<br />
for International Patenting?<br />
对于专利国际申请,什么是非常重要的?<br />
Lack of Novelty (especially, through “inherency”) or<br />
Inventive Step Can Be Problematic, But Descriptive<br />
Insufficiency <strong>Is</strong> A Common Flaw<br />
Documenting Inventive Process <strong>Is</strong> A Foundation for<br />
Adequate Description<br />
缺少新颖性(尤其“固有”的新颖性问题)或创造性,但不<br />
充分公开是比较常见的问题<br />
对于发明过程中文件的详细记录归档是说明书充分公开的<br />
基础<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
9<br />
10<br />
5
Correct Inventorship –<br />
Why Should You Care?<br />
为什么你应当关注正确的发明人?<br />
Incorrect Inventorship:<br />
Basis for Patent Invalidation<br />
Recognition of Contribution<br />
– prestige factor + team building<br />
– inventor compensation<br />
Ownership May Follow Inventorship<br />
US “First to Invent” Rule Values Documenting Evolution of Invention<br />
不正确的发明人:<br />
专利无效理由<br />
对于发明人所作贡献的认可<br />
– 权威因素+团队建设<br />
– 发明人报酬<br />
所有者与发明人之间密切联系<br />
美国专利制度中的“先发明制”使得发明过程中的文件记录归档变得非常重要<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
IP “Due Diligence” Concerns<br />
知识产权“尽职调查”中注意事项<br />
Inventorship and ownership<br />
Quality of intellectual asset portfolio<br />
– Backward / forward benchmarking<br />
– Breadth and term of key patent claims<br />
– Challenge / infringement prospects<br />
Continuity of knowledge base<br />
– Trade secrecy safeguards<br />
– Relationship with critical personnel<br />
发明人和所有者<br />
知识产权组合的资产质量<br />
– 后退/前进基准<br />
– 关键权利要求的宽度以及用语<br />
– 挑战/侵权前景<br />
知识储备的连贯性<br />
– 商业秘密的保护<br />
– 与重要员工关系的维持<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
11<br />
12<br />
6
Lessons Learned<br />
本课程总结<br />
Maximizing IP value depends on innovative<br />
research and on effective business-plan<br />
integration and careful record keeping<br />
Knowledgeable management must<br />
continually reevaluate and refine R&D goals<br />
and related IP strategy<br />
知识产权价值最大化需通过创新型研究以及商业<br />
计划的有效整合和发明过程中良好的记录<br />
知识型管理必须不断地对研发目标和有关地知识<br />
产权战略进行重新评估以及重新界定<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2008 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
©2009 <strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
Stephen A. Bent (柏思迪)<br />
<strong>Foley</strong> & <strong>Lardner</strong> LLP<br />
Washington Harbour<br />
3000 K Street NW, Suite 500<br />
Washington, DC 20007-5143<br />
Phone: (202) 672-5404<br />
Email: sbent@foley.com<br />
柏思迪<br />
美国富理达律师事务所 华盛顿特区办公室<br />
电话: (202) 672-5404<br />
电邮: sbent@foley.com<br />
13<br />
14<br />
7
Change language